Medications
Resources
Basic InformationMore InformationLatest News
Health Tip: Packing Prescriptions for TravelDrug Errors Peak in July When New Docs StartFDA Warns Consumers Against Swallowing Topical BenadrylStudy Shows Some Anti-Seizure Meds Raise Suicide RiskPrescriptions Translated to Spanish Could Be Hazardous to HealthTougher-to-Abuse Form of OxyContin ApprovedVaccines-By-Patch Good News for Needle-PhobicRifaximin Maintains Remission in Patients With Liver DiseaseMenstrual Cramps May Be Helped by New DrugNew Inhaled Insulin Shows Promise for DiabetesPlavix Can Help Cut Death Risk in Certain Heart PatientsFDA Asks Docs to Suspend Using Glaxo Rotavirus VaccineFDA Says High-Dose Simvastatin Ups Myopathy RiskHigh-Dose Zocor Boosts Muscle Injury Risk: FDAAvandia Researchers' Financial Ties QuestionedCarbaglu Approved for Rare Genetic DisorderACC: New Dual-Acting Drug Lowers Blood PressureNewer Blood Thinner Beats Plavix for Bypass PatientsArthritis Drug May Fight Diabetes, Too2 Drugs Fail to Prevent Diabetes in the OverweightFDA Adds Boxed Warning to Clopidogrel LabelThiazolidinediones Not Linked to Diabetic Macular EdemaYoung Kids to Benefit From Broader Pneumococcal VaccineBleeding Alert Sounded for Stroke DrugsLink Between Diabetes and Neuroleptic Drugs OutlinedResistance Likely to Develop With New Hepatitis C DrugsLasofoxifene Examined in Postmenopausal WomenSuccessor to Combination Pneumococcal Vaccine ApprovedMenveo Vaccine Approved for Bacterial MeningitisFDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the MarketRituxan Approved for Chronic Lymphocytic LeukemiaNew Technology Could Widen Reach of VaccinesFDA Issues Warning on Key Asthma DrugsFDA Issues Maalox Total Relief WarningIbuprofen May Help Stave Off Parkinson'sFDA Tightens Controls on Anemia DrugsAdded Drug Aids MS Treatment'Fishy Smell' May Keep Patients From Diabetes DrugBotox May Prevent Some MigrainesAnother Study Refutes Vaccination-Autism LinkCrestor Approval ExpandedParoxetine May Compromise the Efficacy of TamoxifenNeedle Length May Affect Vaccination Results in ObeseDrug May Ease Cognitive Effects of Huntington'sGlaucoma Drugs May Play Role in Longer LifeH1N1 Vaccination Still Highly RecommendedThe Lancet Retracts Study Linking MMR Vaccine, AutismXiaflex Approved for Rare Hand ConditionAntidepressants After Stroke May Boost Mental AbilityFDA Revises Label for the HIV Drug Didanosine
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Major Depression & Unipolar Varieties
Medical Disorders
Mental Disorders
Mental Health Professions

Severely Depressed Gain Most from Antidepressants

HealthDay News
by By Amanda GardnerHealthDay Reporter
Updated: Jan 5th 2010

 

new article illustration

TUESDAY, Jan. 5 (HealthDay News) -- Antidepressants seem to be most effective for the people with the most severe symptoms, new research suggests.

Individuals with mild-to-moderate symptoms may fare no better on antidepressants than on a placebo, say the authors of a new analysis published in the Jan. 6 issue of the Journal of the American Medical Association.

But the findings are not actually that surprising, said one expert, and don't necessarily mean that people with mild-to-moderate depression should not try antidepressants.

"I'm not sure this is a finding that's counter to giving medication to people with mild-to-moderate depression," said Dr. Gregory Asnis, director of the anxiety and depression program at Montefiore Medical Center in New York City.

Even the placebo group showed a response and, over time, the placebo effect tends to wear off, Asnis explained, whereas true drug responders continue to benefit, a difference that might not be evident in the time periods involved in the study.

"The bottom line is even though the benefits of a drug compared with placebo may be most demonstrated in severely ill people, one question is what happens in time," he said. "Placebo frequently fails as time goes on."

The findings follow on the heels of another study, released Jan. 4 in the Archives of General Psychiatry, which reported that one in five U.S. adults fails to get minimum guideline-recommended treatment for depression, and even fewer receive optimal care in minority populations such as Mexican Americans.

The authors of the more recent study scoured results from six previously completed large, randomized and placebo-controlled trials looking at major and minor depression.

Virtually no difference was noted between placebo and medication effects in people who scored lower on depression scales. But as depression severity increased, so did the drug benefits.

According to the study authors, most studies showing a benefit to antidepressants focus on more severely depressed individuals.

They suggested that patients and health-care providers should be aware that antidepressant therapy may not be as beneficial in people with milder forms of the condition.

Many of the study authors reported receiving funding from different pharmaceutical companies, although this study was funded by the National Institute of Mental Health.

More information

The National Institute of Mental Health has more on antidepressants.




Family Service & Community Mental Health Center
4100 Veterans Parkway
McHenry, IL  60050 [map]

815-385-6400


powered by centersite dot net